Biotechnology

Samsung Biologics and AstraZeneca forge strategic manufacturing partnership for global supply

INCHEON, South Korea, Sept. 21, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million. Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Pla...

2020-09-22 07:00 12804

PharmAbcine expands partnership with Samsung Biologics for PMC-403

DAEJEON, South Korea, Sept. 21, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Samsung Biologics (KRX: 207940.KS) for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular ...

2020-09-21 20:00 1723

Expanding Their Existing Strategic Collaboration, GenScript ProBio Licensed Global Rights to Develop and Commercialize a SMAB Bispecific Antibody Molecule to REMD Biotherapeutics Inc.

NANJING, China, Sept. 17, 2020 /PRNewswire/ -- On September 16th, 2020, GenScript ProBio and REMD Biotherapeutics Inc. (REMD) announced that REMD has licensed a bispecific antibody derived from the Single-domain antibody fused to Monoclonal Ab (SMAB) platform developed by GenScript ProBio. REMD i...

2020-09-17 22:00 2228

Samsung Biologics signs development agreement with Panolos for solid tumor treatment

INCHEON, South Korea, Sept. 16, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors. Under this agreement, Samsung Biologics will provide a full scope of its developm...

2020-09-17 08:43 2620

Less is more: Novel algorithm automatically removes poor-quality data to improve AI scalability

SAN FRANCISCO, Sept. 15, 2020 /PRNewswire/ -- AI Healthcare company Presagen has developed a novel technique that is able to automatically clean poor-quality data needed to train scalable and reliable Artificial Intelligence products.

2020-09-16 22:50 1959

Transcenta Successfully Scaled up the Continuous Perfusion Process and Completed GMP Manufacturing of a Novel Bispecific Antibody for Cancer Immunotherapy

SUZHOU, China and HANGZHOU, China, Sept. 15, 2020 /PRNewswire/ -- Transcenta, a global biotherapeutics company, today announced success in scaling up the continuous perfusion process to 200L and completion of GMP production of a bispecific antibody for a Phase 1 clinical study.  "This is an impo...

2020-09-15 23:00 1702

PharmAbcine Unveils Olinvacimab's Positive Results from Phase Ib Combination Studies at KSMO 2020

DAEJEON, South Korea, Sept. 14, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) today announced positive data from its two combination trials of olinvacimab, its leading clinical candidate in oncology, with MSD's pembrolizumab at the 13th Annual Meeting of the Korean Society of Medical O...

2020-09-14 20:00 1683

NaviFUS Launches Neuronavigation-guided Clinical Trial to Open the Blood-Brain-Barrier for Combination FUS-Bevacizumab Therapy in rGBM Patients

TAIPEI, Sept. 11, 2020 /PRNewswire/ -- Genovate Biotech (TPEX:4130) subsidiary andTaiwan-based focused ultrasound (FUS) manufacturer NaviFUS Corporation is pleased to announce the start of its clinical trial (NCT04446416) for the combination of FUS plus bevacizumab therapy. Researchers at Linkou ...

2020-09-11 20:55 3941

CMAB Biopharma and Laekna Therapeutics Enter Strategic Agreement for LAE005 Global Development and Commercialization Partnership

SUZHOU, China, Sept. 10, 2020 /PRNewswire/ -- CMAB Biopharma (Suzhou) Inc. ("CMAB"), and Laekna Therapeutics Shanghai Co., Ltd. ("Laekna Therapeutics"), today announced a strategic collaboration agreement in Suzhou BioBAY for speedup of Immune Checkpoint Inhibitor (ICI) drug candidate to the clin...

2020-09-10 20:08 2160

Happiness Biotech Launched "Happy Buy", Dedicated to Boost its E-Commerce Business

NANPING, China, Sept. 9, 2020 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer, announced today that the Company has set up a wholly owned subsidiary "Happy Buy (Fujian) Internet Technology Co....

2020-09-09 22:00 10658

Clarity Pharmaceuticals Announces the US FDA Grants Rare Paediatric Disease Designation to 64Cu-SARTATE™, a diagnostic for the clinical management of neuroblastoma

SYDNEY, Sept. 9, 2020 /PRNewswire/ -- Clarity Pharmaceuticals, a clinical-stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Rare Paediatric Disease Designation (RPDD) to64Cu-SARTATE™, ...

2020-09-09 21:13 1804

Seegene introduces a High-throughput 8-plex Test for Flu A, Flu B, RSV and COVID-19 with dual internal controls

SEOUL, South Korea, Sept. 8, 2020 /PRNewswire/ -- Seegene, Inc. introduced a single tube real-time RT-PCR assay, Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay, which simultaneously detects and differentiates Flu A, Flu B, RSV A/B, and three different target genes of COVID-19 (S gene, RdRP gene and N ge...

2020-09-08 20:00 2446

Life After Covid-19: Big Questions on Medical and Bio-Engineering

DAEJEON, South Korea, Sept. 8, 2020 /PRNewswire/ -- On September 9, the Global Strategic Institute at KAIST will delve into innovative future strategies for the medical and bio-engineering sectors that have been disrupted by COVID-19. The forum will live stream via YouTube, KTV, and Naver TV from...

2020-09-08 15:52 2015

Transcenta Holding Announces Appointment of Dr. Charlie Qi as Senior Vice President of Global Clinical Development

SUZHOU, China, Sept.7, 2020 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the appointment of Dr.Charlie Qi as its Senior Vice...

2020-09-07 23:00 1706

PharmAbcine is presenting at the KSMO 2020

DAEJEON, South Korea, Sept. 2, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotechnology company in South Korea, announced today that onSeptember 4th, the company will present the interim data of its ongoing IO combo clinical trials at KSMO 2020. KSMO 2020 is the...

2020-09-02 21:00 2068

PharmAbcine signs a CMO contract with Binex so Binex can produce olinvacimab at its new 5,000L production line

DAEJEON, South Korea, Sept. 2, 2020 /PRNewswire/ -- PharmAbcine (KRX: 208340ks), a biotech company focusing on the development of antibody therapeutics, announcedon August 31 that it had signed a contract manufacturing organization(CMO) agreement with Binex, a leading biologics CDMO(Contract Dev...

2020-09-02 21:00 1964

Clene Nanomedicine, Inc. to go Public through Merger with Tottenham Acquisition I Limited

* Clene is a clinical-stage biopharmaceutical company developing the first potential therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neur...

2020-09-02 20:00 18848

bitBiome has raised 700 million JPY in Seed financing

TOKYO, Sept. 1, 2020 /PRNewswire/ -- bitBiome, Inc., an emerging leader in microbiome analytics, has raised700 million JPY (approx. $6.6m US) in seed financing from previous and new investors including TheUniversity of Tokyo Edge Capital Partners, Universal Materials Incubator, and otherJapan-ba...

2020-09-02 11:28 1908

Origin Agritech to Present at The LD 500 Virtual Conference

BEIJING,, Aug. 31, 2020 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED)  (the "Company" or "Origin"), an agriculture technology company, today announced that it will be presenting at the LD 500 investor conference on Friday, September 4th at8 AM PST / 11 AM EST. Origin's Chairman and Chief Ex...

2020-09-01 01:41 16892

Transcenta Announces First Patient Dosed in Phase I China Trial of Claudin18.2 Targeting Monoclonal Antibody TST001

SUZHOU, China, Aug. 31, 2020 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced today that the first subject has been dosed successful...

2020-08-31 23:00 2025
1 ... 117118119120121122123 ... 129